Low-energy Shock Waves Promote the Cisplatin Chemosensitivity of Human Osteosarcoma MNNG/HOS Cells Via the P2X7/Akt/mTOR Pathway

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2024 May 2

PMID 38694312

Authors

Ning Gai

Wei-Na Ju

Tie-Cheng Yu

Bao-Chang Qi

Affiliations

Soon will be listed here.

Abstract

Background: The current dilemma of osteosarcoma treatment is the resistance of chemotherapeutic drugs after long-term usage, which also introduces life-threatening side effects.

Methods And Results: To minimize chemoresistance in osteosarcoma patients, the authors applied shock waves (SWs) to human osteosarcoma MNNG/HOS cells, then evaluated the cell viability and extracellular ATP levels, and further investigated the effect of SWs on cisplatin (DDP) cytotoxicity in MNNG/HOS cells. The authors' results showed that 400 SW pulses at 0.21 mJ/mm exhibited little influence on the MNNG/HOS cell viability. In addition, this SW condition significantly promoted the extracellular ATP release in MNNG/HOS cells. Importantly, low-energy SWs obviously increased Akt and mammalian target of rapamycin (mTOR) phosphorylation and activation in MNNG/HOS cells, which could be partially reversed in the presence of P2X7 siRNA. The authors also found that low-energy SWs strongly increased the DDP sensitivity of MNNG/HOS cells in the absence of P2X7.

Conclusions: For the first time, the authors found that SW therapy reduced the DDP resistance of MNNG/HOS osteosarcoma cells when the ATP receptor P2X7 was downregulated. SW therapy may provide a novel treatment strategy for chemoresistant human osteosarcoma.

References

Di Virgilio F, Jiang L, Roger S, Falzoni S, Sarti A, Vultaggio-Poma V . Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells. Methods Enzymol. 2019; 629:115-150. DOI: 10.1016/bs.mie.2019.07.043. View

Pena M, Delgado-Gonzalez E, Lopez-Marin L, Millan-Chiu B, Fernandez F, Rodriguez-Castelan J . Shock Wave Application Increases the Antineoplastic Effect of Molecular Iodine Supplement in Breast Cancer Xenografts. Ultrasound Med Biol. 2019; 46(3):649-659. DOI: 10.1016/j.ultrasmedbio.2019.11.015. View

Ji Z, Xie Y, Guan Y, Zhang Y, Cho K, Ji M . Involvement of P2X Receptor in Proliferation and Migration of Human Glioma Cells. Biomed Res Int. 2018; 2018:8591397. PMC: 5818963. DOI: 10.1155/2018/8591397. View

Bramer J, van Linge J, Grimer R, Scholten R . Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol. 2009; 35(10):1030-6. DOI: 10.1016/j.ejso.2009.01.011. View

White N, Butler P, Burnstock G . Human melanomas express functional P2 X(7) receptors. Cell Tissue Res. 2005; 321(3):411-8. DOI: 10.1007/s00441-005-1149-x. View

Amoroso F, Salaro E, Falzoni S, Chiozzi P, Giuliani A, Cavallesco G . P2X7 targeting inhibits growth of human mesothelioma. Oncotarget. 2016; 7(31):49664-49676. PMC: 5226537. DOI: 10.18632/oncotarget.10430. View

Lopez-Marin L, Rivera A, Fernandez F, Loske A . Shock wave-induced permeabilization of mammalian cells. Phys Life Rev. 2018; 26-27:1-38. DOI: 10.1016/j.plrev.2018.03.001. View

Yamamoto N, Tsuchiya H . Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going?. Expert Opin Pharmacother. 2013; 14(16):2183-93. DOI: 10.1517/14656566.2013.827171. View

Bian S, Sun X, Bai A, Zhang C, Li L, Enjyoji K . P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death. PLoS One. 2013; 8(4):e60184. PMC: 3615040. DOI: 10.1371/journal.pone.0060184. View

10.

Foglietta F, Canaparo R, Francovich A, Arena F, Civera S, Cravotto G . Sonodynamic treatment as an innovative bimodal anticancer approach: shock wave-mediated tumor growth inhibition in a syngeneic breast cancer model. Discov Med. 2015; 20(110):197-205. View

11.

Mirabello L, Troisi R, Savage S . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-43. PMC: 2813207. DOI: 10.1002/cncr.24121. View

12.

Zhu X, Li Q, Song W, Peng X, Zhao R . P2X7 receptor: a critical regulator and potential target for breast cancer. J Mol Med (Berl). 2021; 99(3):349-358. DOI: 10.1007/s00109-021-02041-x. View

13.

Vazquez-Cuevas F, Martinez-Ramirez A, Robles-Martinez L, Garay E, Garcia-Carranca A, Perez-Montiel D . Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells. J Cell Biochem. 2014; 115(11):1955-66. DOI: 10.1002/jcb.24867. View

14.

Palmero A, Berger M, Venturi C, Ferrero I, Rustichelli D, Berta L . High energy shock waves enhance the cytotoxic effect of doxorubicin and methotrexate to human osteosarcoma cell lines. Oncol Rep. 2005; 15(1):267-73. View

15.

Choi J, Ji Y, Ko J, Cho H, Lee D . Activating P2X7 Receptors Increases Proliferation of Human Pancreatic Cancer Cells via ERK1/2 and JNK. Pancreas. 2018; 47(5):643-651. DOI: 10.1097/MPA.0000000000001055. View

16.

Rinella L, Pizzo B, Frairia R, Delsedime L, Calleris G, Gontero P . Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression. Prostate. 2020; 80(13):1087-1096. DOI: 10.1002/pros.24037. View

17.

Zhang Y, Cheng H, Li W, Wu H, Yang Y . Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling. Int J Cancer. 2019; 145(4):1068-1082. PMC: 6618011. DOI: 10.1002/ijc.32207. View

18.

Elkashef A, Barakat N, Khater S, Awadalla A, Belal F, El-Assmy A . Effect of low-energy shock wave therapy on intravesical epirubicin delivery in a rat model of bladder cancer. BJU Int. 2020; 127(1):80-89. DOI: 10.1111/bju.15173. View

19.

Qi B, Yu T, Wang C, Wang T, Yao J, Zhang X . Shock wave-induced ATP release from osteosarcoma U2OS cells promotes cellular uptake and cytotoxicity of methotrexate. J Exp Clin Cancer Res. 2016; 35(1):161. PMC: 5048460. DOI: 10.1186/s13046-016-0437-5. View